OBJECTIVE: A review of stereotactic body radiotherapy (SBRT) for oligometastases defined as three or fewer sites of isolated metastatic disease. The aim was to identify local control, overall survival (OS) and progression-free survival (PFS) of patients receiving SBRT for oligometastatic (OM) disease. METHODS: Data were analysed for SBRT delivered between 01 September 2010 and 31 March 2014. End points included local control, PFS, OS and toxicity. RESULTS: 76 patients received SBRT. The median age was 60 years (31-89 years). 44 were male. Median follow-up was 12.3 months (0.2-36.9 months). Major primary tumour sites included colorectal (38%), the breast (18%) and the prostate (12%). The treatment sites included lymph nodes (42%), the bone and spine (29%) and soft tissue (29%). 42% were previously treated with conventional radiotherapy. 45% were disease free after SBRT. 4% had local relapse, 45% had distant relapse, and 6% had local and distant relapse. Local control was 89%. The OS was 84.4% at 1 year and 63.2% at 2 years. PFS was 49.1% at 1 year and 26.2% at 2 years. Toxicities included duodenal ulcer and biliary stricture formation. CONCLUSION: SBRT can achieve durable control of OM lesions and results in minimal radiation-induced morbidity. ADVANCES IN KNOWLEDGE: This cohort is one of the largest reported to date and contributes to the field of SBRT in oligometastases that is emerging as an important research area. It is the only study reported from the UK and uses a uniform technique throughout. The efficacy and low toxicity with durable control of local disease with this approach is shown, setting the foundations for future randomized studies.
OBJECTIVE: A review of stereotactic body radiotherapy (SBRT) for oligometastases defined as three or fewer sites of isolated metastatic disease. The aim was to identify local control, overall survival (OS) and progression-free survival (PFS) of patients receiving SBRT for oligometastatic (OM) disease. METHODS: Data were analysed for SBRT delivered between 01 September 2010 and 31 March 2014. End points included local control, PFS, OS and toxicity. RESULTS: 76 patients received SBRT. The median age was 60 years (31-89 years). 44 were male. Median follow-up was 12.3 months (0.2-36.9 months). Major primary tumour sites included colorectal (38%), the breast (18%) and the prostate (12%). The treatment sites included lymph nodes (42%), the bone and spine (29%) and soft tissue (29%). 42% were previously treated with conventional radiotherapy. 45% were disease free after SBRT. 4% had local relapse, 45% had distant relapse, and 6% had local and distant relapse. Local control was 89%. The OS was 84.4% at 1 year and 63.2% at 2 years. PFS was 49.1% at 1 year and 26.2% at 2 years. Toxicities included duodenal ulcer and biliary stricture formation. CONCLUSION: SBRT can achieve durable control of OM lesions and results in minimal radiation-induced morbidity. ADVANCES IN KNOWLEDGE: This cohort is one of the largest reported to date and contributes to the field of SBRT in oligometastases that is emerging as an important research area. It is the only study reported from the UK and uses a uniform technique throughout. The efficacy and low toxicity with durable control of local disease with this approach is shown, setting the foundations for future randomized studies.
Authors: Stanley H Benedict; Kamil M Yenice; David Followill; James M Galvin; William Hinson; Brian Kavanagh; Paul Keall; Michael Lovelock; Sanford Meeks; Lech Papiez; Thomas Purdie; Ramaswamy Sadagopan; Michael C Schell; Bill Salter; David J Schlesinger; Almon S Shiu; Timothy Solberg; Danny Y Song; Volker Stieber; Robert Timmerman; Wolfgang A Tomé; Dirk Verellen; Lu Wang; Fang-Fang Yin Journal: Med Phys Date: 2010-08 Impact factor: 4.071
Authors: Robert McCammon; Tracey E Schefter; Laurie E Gaspar; Rebekah Zaemisch; Daniel Gravdahl; Brian Kavanagh Journal: Int J Radiat Oncol Biol Phys Date: 2008-09-09 Impact factor: 7.038
Authors: Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2009-12-08 Impact factor: 66.675
Authors: Sun Hyun Bae; Mi-Sook Kim; Chul Koo Cho; Jin-Kyu Kang; Hye Jin Kang; Young Han Kim; Ui-Sup Shin; Sun Mi Moon; Dong Han Lee Journal: J Surg Oncol Date: 2012-02-01 Impact factor: 3.454
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Michael T Milano; Alan W Katz; Ann G Muhs; Abraham Philip; Daniel J Buchholz; Michael C Schell; Paul Okunieff Journal: Cancer Date: 2008-02-01 Impact factor: 6.860
Authors: David A Palma; Cornelis J A Haasbeek; George B Rodrigues; Max Dahele; Michael Lock; Brian Yaremko; Robert Olson; Mitchell Liu; Jason Panarotto; Gwendolyn H M J Griffioen; Stewart Gaede; Ben Slotman; Suresh Senan Journal: BMC Cancer Date: 2012-07-23 Impact factor: 4.430
Authors: Alissar El Chediak; Ali Shamseddine; Larry Bodgi; Jean-Pierre Obeid; Fady Geara; Youssef H Zeidan Journal: Med Oncol Date: 2017-08-21 Impact factor: 3.064
Authors: Chang Heon Choi; So-Yeon Park; Jung-In Kim; Jin Ho Kim; Kyubo Kim; Joel Carlson; Jong Min Park Journal: Br J Radiol Date: 2016-12-08 Impact factor: 3.039
Authors: Alina Mihai; Yijia Mu; John Armstrong; Mary Dunne; Sushil Beriwal; Luke Rock; Pierre Thirion; Dwight E Heron; Brian Healy Bird; Jennifer Westrup; Conleth Gerard Murphy; M Saiful Huq; Raymond McDermott Journal: J Radiosurg SBRT Date: 2017
Authors: Christopher L Tinkle; Charu Singh; Shane Lloyd; Yian Guo; Yimei Li; Alberto S Pappo; Steven G DuBois; John T Lucas; Daphne A Haas-Kogan; Stephanie A Terezakis; Steve E Braunstein; Matthew J Krasin Journal: Int J Radiat Oncol Biol Phys Date: 2020-11-28 Impact factor: 7.038